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The Effects of Metformin on the Glucose Metabolism in Lactobacillus acidophilus
By: Elizabeth Daniels, Kaitlin Doucette, Neha Amatya, Ashley Shuck, Dr. Myoung Lee
Winona State University Department of Chemistry
5/2/14

ABSTRACT
Metformin (1,1-dimethylbiguanide) is an anti-hyperglycemic agent that is commonly used in the
oral treatment of Type 2 Diabetes Mellitus. Phenformin (phenethylbiguanide) is its structural
analog. As an anti-hyperglycemic agent, metformin is known to affect glucose transporters.
Lactobacillus acidophilus is a bacteria that ferments lactic acid under anaerobic conditions and
is known to contain numerous glucose transporters. Inconclusive results were seen during NMR
analysis due to the lack of lactic acid and the increase of glucose over time. With completely
anaerobic conditions and longer measurement periods, it is hopeful that further
experimentation will be successful. Adenosine deaminase is involved in purine nucleoside
metabolism. Based on molecular docking simulations, we have hypothesized that adenosine
deaminase could be inhibited by metformin and phenformin, and that phenformin is a better
inhibitor than metformin. The inhibitory effect of metformin and phenformin on adenosine
deaminase from bovine spleen was studied spectrophotometrically. Non-linear regression
analysis was used to obtain the inhibition constants. Metformin was a competitive inhibitor of
deamination of adenosine with the inhibition constant, KI, of 88 mM. Phenformin was slightly
more effective than metformin as a competitive inhibitor with KI of 10 mM. The KM of
adenosine was 31 μM. The inhibition constant values indicate that neither metformin nor
phenformin is a potent inhibitor of adenosine deaminase. It is unlikely that at the physiological
concentration, adenosine deaminase activity would be greatly affected by either drug.

INTRODUCTION
Diabetes Mellitus is an increasingly prevalent disease that affects an estimated 25.8 million
people in the United States alone.1 The majority of these people are diagnosed as having Type 2
Diabetes Mellitus (T2DM). T2DM is characterized by insulin resistance resulting in abnormally
high blood glucose levels due to the inability of glucose uptake by cells.2 Along with careful
regulation and monitoring of blood glucose levels, T2DM patients can also be prescribed other
treatment options, such as metformin. Metformin is a biguanide, antihyperglycemic agent that
is known to lower blood glucose concentration, increase glucose uptake in cells, and improve
insulin sensitivity.3 Phenformin was another treatment option similar to metformin, until it was
taken off the market due to problems associated with lactic acidosis.4

Figure 1: Structure of Metformin

Figure 2: Structure of Phenformin

There are several proposed mechanisms associated with the specific functioning of metformin
within Type 2 Diabetics. The most commonly accepted mechanisms involve the inhibition of
AMP deaminase (AMPD), an enzyme the converts AMP into IMP, and mitochondrial complex 1,
an enzyme in the electron transport chain. Together, the inhibition of both of these enzymes
essentially increase the concentration of AMP, stimulating AMP-activated protein kinase
(AMPK).3 Activation of AMPK causes the inhibition of synthetic pathways including
gluconeogenesis and fatty acid synthesis; and, the stimulation of catabolic pathways including
glucose degradation and β-oxidation.3 Adenosine deaminase (ADA), an enzyme that converts
adenosine into inosine, has a similar function as AMPD.5 Comparatively speaking, researching
the inhibition of ADA by metformin will help extrapolate inhibition of AMPD. Molecular docking
simulations, seen below, show that metformin will bind tightly and similarly to adenine at the
active site on ADA.

Figure 3: Metformin bound to ADA

Figure 4: Adenine bound to ADA

In addition to studying the effects of metformin on certain enzymes, glucose transporters were
also studied using Lactobacillus acidophilus, a bacterium primarily functioning to ferment sugar
into lactic acid.6 Since this bacterium is known to metabolize glucose into lactic acid, its
membrane contains numerous glucose transporters.6 In general, metformin increases uptake of
glucose in cells; however, it is unclear exactly how metformin interacts mechanistically with
glucose transporters.

EXPERIMENTAL PROCEDURE
To study glucose transporters, Lactobacillus acidophilus 4365 and its recommended growth
media 416 was purchased from ATCC. The Lactobacilli MRS broth (BD 288130) was made using
55 grams/ 1 L. A total of 2 Liters of broth was made and autoclaved at 121 degrees Celsius to
ensure sterility. A small sample of 24 hour incubation cells were prepared at 80 rpm at 35.5
degrees Celsius. The broth was a dark brown color, when cells started growing the broth-cell
solution turned a lighter brown color and had a cloudy appearance. Next, the rate of bacterial
growth was measured over time using a broth sample as the standard auto-zero. The cells from
the 24 hour incubation small sample were measured to have an absorbance of 1.61 at 600 nm
wavelength using UV-vis spectroscopy. Bacterial growth measurements were taken from
samples prepared with 25 mL MRS broth to 1 mL of small sample incubation cells every 30
minutes until growth increase plateaued based on the absorbance values at 600 nm. Growth
was slow but leveled off around 14 hours; the primary growth slope took approximately 10
hours as seen in the Graph below. A large culture of Lactobacillus acidophilus was then made
using this timeframe at the same incubation settings.
The cells were centrifuged at 1500 rpm for 10 minutes and the supernatant was discarded. 10
mL of Buffer A was added per gram of cell; there was 1.457 grams of cells so 14.57 mL of buffer
was added. The cells were combined into the same test tube and the following solutions were
made according to Table 1 and Table 2. The solutions were vortexed and incubated for the
allotted time (Note that 0 minutes indicates the cells should be killed immediately).

Table 1: Control Solutions
Tube
Cell Suspension
(mL)
1
2
3
4
5
6

1
1
1
1
1
1

DI Water (mL)

0.025
0.025
0.025
0.025
0.025
0.025

200 mg/mL
Labeled Glucose
(mL)
0.025
0.025
0.025
0.025
0.025
0.025

Incubation Time
(minutes)
0
2
4
6
8
10

Table 2: Metformin Solutions
Tube
Cell Suspension
(mL)
1
2
3
4
5
6

1
1
1
1
1
1

500 mM
Metformin (mL)
0.025
0.025
0.025
0.025
0.025
0.025

200 mg/mL
Labeled Glucose
(mL)
0.025
0.025
0.025
0.025
0.025
0.025

Incubation Time
(minutes)
0
2
4
6
8
10

After the incubation time is complete, the cells were killed with 0.125 mL of 70% perchloric
acid. The cells were then broken up by freezing each tube in liquid nitrogen and thawing in
water bath three times. Then, the solutions were centrifuged at 2,000 rmp for 2 minutes. 0.145
mL of 10M KOH was added to the solution for neutralization. Then, 0.122 mL D 2O was added
and the tubes were centrifuged at 5,000 rpm for two minutes in order to remove any
precipitates. The supernatant was then removed using a pipet, making sure not to disturb the
pellet, and transferred into a clean NMR tube. The 13C NMR was done using D2O for locking and
100 proton-decoupled scans per spectrum were collected.
In the next experiment, the inhibition of ADA obtained from bovine spleen by antihyperglycemic agents metformin and phenformin was studied. The activity of ADA was
measured through continuous spectrophotometric rate determination via UV-vis
spectrophotometer at a 265 nm wavelength. Quartz cuvettes containing a 50 mM phosphate
buffer at pH 7.4 and adenosine concentrations ranging from 15 µM to 133 µM provided a
control group. Metformin was studied at concentrations of 10 mM, 20 mM, and 40 mM while
phenformin was studied at concentrations of 2 mM, 3.3 mM, 4 mM, and 30 mM. All chemicals
used in these reactions were purchased from Sigma-Aldrich. The data obtained was used to
calculate ADA activity and was used to create a nonlinear regression graph. Through non-linear
regression analysis of these graphs, calculations of Vmax, Km, and KI were carried out in order to
help characterize the type of inhibition metformin and phenformin present on adenosine
deaminase.
It is important to note that this report was done to describe the experiments pertaining to
glucose transporters in Lactobacillus acidophilus. The adenosine deaminase experiment was
included to help describe further experiments done on a similar topic that help in
understanding and analyzing this particular research experiment.

RESULTS AND DISCUSSION
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Graph 1: Growth Rate of Lactobacillus acidophilus as a Function of Absorbance

Table 3: NMR Data for Control Solutions
β-Glucose
Time
Peak (ppm) Peak Height
[abn]
0
96.0
0.75183
2
96.0
1.35312
4
95.9
1.10188
6
95.9
1.21526
8
95.9
1.07791
10
95.9
1.14678

α-Glucose
Peak (ppm) Peak Height
[abn]
92.2
0.41317
92.2
0.6978
92.17
0.6444
92.17
0.69443
92.18
0.57009
92.16
0.60712

Table 4: NMR Data for Metformin Solutions
β-Glucose
Time
Peak (ppm) Peak Height
[abn]
0
96.0
1.44792
2
95.9
1.23372
4
95.8
0.74083
6
95.7
0.71139
8
95.9
1.13356
10
96.0
1.17733

α-Glucose
Peak (ppm) Peak Height
[abn]
92.1
0.81084
92.1
0.63353
92.1
0.30322
92.0
0.25662
92.17
0.61201
92.18
0.66894

Spectra 1: Sample 1 NMR spectrum

Spectra 2: Sample 6 NMR spectrum

Spectra 3: Sample 11 NMR spectrum

Spectra 4: Sample 16 NMR spectrum
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Graph 2: Peak Height vs. Incubation Time for Beta Glucose
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Graph 3: Peak Height vs. Incubation Time for Alpha Glucose

The data seen above shows inconclusive results. All spectra analyzed showed peaks around 96
ppm and 92 ppm. Using the Spectral Database for Organic Compounds SDBS, it was determined
that the peak at 96 ppm represents β-glucose while the peak at 92 ppm represents α-glucose.7
It was expected that the spectra would show a lactic acid peak in Sample 6 and Sample 16 due
to the cells undergoing lactic acid fermentation. However, this is not seen in those respective
spectra’s. This could be due to the fact that the cells were not under completely anaerobic
conditions, which allowed them to carry out aerobic respiration. If the cells were going through
aerobic respiration, the labeled glucose would disappear as carbon dioxide released from the
citric acid cycle, and thus the α-glucose and β-glucose peaks would show a decreased peak
height (Since carbon dioxide is released as a gas, it cannot be picked up by NMR analysis so a
peak will not be present). Unfortunately, this is not seen in Graphs 2 and 3 due to the fact that
the amount of glucose increases. In future studies, the cells can be flushed with nitrogen gas to
ensure completely anaerobic conditions. Also, the measurements can be made over a longer
period of time, allowing the cells more time to undergo metabolism of glucose.

Graph 4: Nonlinear Regression Plot for 20 mM Metformin

Graph 5: Nonlinear Regression Plot for 3.3 mM Phenformin

Table 5: Nonlinear Regression Analysis
Metformin
Concentration (mM)
20
Vmax (µmol inosine/min/mL ADA)
28
Km (µM)
31
KI (mM)
88
Mode of Inhibition
Competitive

Phenformin
3.3
28
31
10
Competitive

It was determined that the Km value is equal to 31 µM. The KI for 20 mM metformin is 88 mM
while the KI for 3.3 mM phenformin is 10 mM as seen in Table 3. Since both KI values are larger
than the Km, it can be assumed that the inhibitors reduce the binding affinity of the enzyme.
Phenformin has a smaller KI value than metformin indicating that it is better at inhibiting ADA
activity. The Vmax values are very similar; therefore, it can be said that the total amount of
substrate being converted into product is similar in all three cases. This suggests that the
inhibitor reduces the affinity of the enzyme for the substrate but does not decrease the ability
of the enzyme to convert substrate into product if the substrate were to bind to it. Thus, the
mode of inhibition of metformin and phenformin is competitive. The actual substrate binds
tighter to the enzyme than either inhibitor is able to, implying that a subtle competitive
inhibition is taking place.

CONCLUSION
In conclusion, it has been determined by nonlinear regression analysis that ADA activity is
competitively inhibited by metformin and phenformin. However, the competitive inhibition is
subtle due to the fact that the adenosine substrate has a higher binding affinity toward ADA in
a comparison to the inhibitors, metformin and phenformin. As for the experiment involving
glucose transporters in Lactobacillus acidophilus, the NMR results were inconclusive due to the
lack of a peak representing lactic acid, initially suggesting that aerobic respiration was taking
place. However, the amount of glucose seen in the spectrum did not decrease as should be
seen in aerobic respiration by the release of carbon dioxide in the citric acid cycle.
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